

EMA/356072/2020

European Medicines Agency decision

P/0253/2020

of 15 July 2020

on the acceptance of a modification of an agreed paediatric investigation plan for doravirine / lamivudine / tenofovir disoproxil (fumarate) (Delstrigo), (EMA-001695-PIP01-14-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0253/2020

of 15 July 2020

on the acceptance of a modification of an agreed paediatric investigation plan for doravirine / lamivudine / tenofovir disoproxil (fumarate) (Delstrigo), (EMA-001695-PIP01-14-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0140/2016 issued on 20 May 2016 and the decision P/0116/2017 issued on 28 April 2017,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc on 21 February 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 June 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and to the waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral and to the waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for doravirine / lamivudine / tenofovir disoproxil (fumarate) (Delstrigo), tablet, granules, oral use, including changes to the deferral and to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., Clos du Lynx, 5, B-1200 - Brussels, Belgium.

EMA/PDCO/139628/2020 Corr
Amsterdam, 29 May 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001695-PIP01-14-M03

Scope of the application

Active substance(s):

Doravirine / lamivudine / tenofovir disoproxil (fumarate)

Invented name:

Delstrigo

Condition(s):

Treatment of human immunodeficiency virus-1 (HIV-1) infection

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Granules

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc submitted to the European Medicines Agency on 21 February 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0140/2016 issued on 20 May 2016 and the decision P/0116/2017 issued on 28 April 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and to the waiver.

The procedure started on 31 March 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral and to the waiver in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of human immunodeficiency virus-1 (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- granules, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

And

- the paediatric population from birth to less than 12 years of age and weighing less than 35Kg;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Treatment of human immunodeficiency virus type 1 (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Antiretroviral combination therapy, for the treatment of HIV-1 infection in adults and in children aged 6 to 18 years

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Granules

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate oral solid dosage form for the fixed dose combination doravirine, lamivudine, tenofovir disoproxil fumarate.

Non-clinical studies	2	Study 2 Dose range-finding juvenile toxicity study. Study 3 Definitive juvenile toxicity study.
Clinical studies	5	Study 4 Open-label two periods trial to evaluate pharmacokinetic, safety, and activity, of doravirine and doravirine fixed dose combination (FDC) with lamivudine and tenofovir disoproxil fumarate in HIV-1 infected adolescents from 12 to less than 18 years of age weighing at least 35 kg. Study 5 Open-label pharmacokinetic with sentinel cohort, safety, and activity study of doravirine in HIV-1 paediatric patients who are (at least 4 weeks and) less than 12 years of age. Study 6 Relative bioavailability study with doravirine adult oral granules to be part of the fixed dose combination in healthy adults. Study 7 Relative bioavailability study with doravirine age appropriate oral granules new formulation as be part of the fixed dose combination. Study 8 Relative bioavailability study with lamivudine and tenofovir disoproxil fumarate age appropriate formulations to be part of the fixed dose combination in healthy adults Study 9 Study deleted in procedure EMEA-001695-PIP01-14-M01.
Extrapolation, modelling and simulation studies	1	Study 10 Modelling and simulation and extrapolation study of the use of doravirine in paediatric patients (from birth to) less than 18 years of age and of the use of the FDC of DOR/3TC/TDF in children aged 6 to less than 18 years.
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of HIV-1

Authorised indication(s):

- Delstrigo is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir

Authorised pharmaceutical form(s):

Film-coated tablets.

Authorised route(s) of administration:

Oral use.